Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules.

Published

Journal Article

BACKGROUND AND OBJECTIVES: Although both licensed rotavirus vaccines are safe and effective, it is often not possible to complete the schedule by using the same vaccine formulation. The goal of this study was to investigate the noninferiority of the immune responses to the 2 licensed rotavirus vaccines when administered as a mixed schedule compared with administering a single vaccine formulation alone. METHODS: Randomized, multicenter, open-label study. Healthy infants (6-14 weeks of age) were randomized to receive rotavirus vaccines in 1 of 5 different schedules (2 using a single vaccine for all doses, and 3 using mixed schedules). The group receiving only the monovalent rotavirus vaccine received 2 doses of vaccine and the other 4 groups received 3 doses of vaccine. Serum for immunogenicity testing was obtained 1 month after the last vaccine dose and the proportion of seropositive children (rotavirus immunoglobulin A ≥20 U/mL) were compared in all the vaccine groups. RESULTS: Between March 2011 and September 2013, 1393 children were enrolled and randomized. Immune responses to all the sequential mixed vaccine schedules were shown to be noninferior when compared with the 2 single vaccine reference groups. The proportion of children seropositive to at least 1 vaccine antigen at 1 month after vaccination ranged from 77% to 96%, and was not significantly different among all the study groups. All schedules were well tolerated. CONCLUSIONS: Mixed schedules are safe and induced comparable immune responses when compared with the licensed rotavirus vaccines given alone.

Full Text

Duke Authors

Cited Authors

  • Libster, R; McNeal, M; Walter, EB; Shane, AL; Winokur, P; Cress, G; Berry, AA; Kotloff, KL; Sarpong, K; Turley, CB; Harrison, CJ; Pahud, BA; Marbin, J; Dunn, J; El-Khorazaty, J; Barrett, J; Edwards, KM; VTEU Rotavirus Vaccine Study Work Group,

Published Date

  • February 2016

Published In

Volume / Issue

  • 137 / 2

Start / End Page

  • e20152603 -

PubMed ID

  • 26823540

Pubmed Central ID

  • 26823540

Electronic International Standard Serial Number (EISSN)

  • 1098-4275

Digital Object Identifier (DOI)

  • 10.1542/peds.2015-2603

Language

  • eng

Conference Location

  • United States